Previous Next

ARCHIVE

№3' 2020

OBSTETRICS AND GYNECOLOGY

International Medical Journal, Vol. 26., Iss. 3, 2020, P. 34−40.

DOI (https://doi.org/10.37436/2308-5274-2020-3-7)

MODERN PRINCIPLES OF MANAGEMENT OF WOMEN WITH ABNORMAL UTERINE BLEEDING, TAKING INTO ACCOUNT THE BLOOD COAGULATION SYSTEM STATE

Kharkiv National Medical University, Ukraine

Abnormal uterine bleeding in women of childbearing potential requires effective emergency care. To determine the features of disorders in the hemostasis system, 120 women were directly examined at the time of bleeding on admission to the hospital, during treatment on days 5−7 of the menstrual cycle, as well as after 6−12 months from the end of treatment. Determination of congenital and acquired defects of the hemostasis system became the main criterion for the selection of combined and isolated forms of abnormal uterine bleeding. Treatment measures for patients were etiopathogenetically selected and individually the intensity of bleeding, the degree of anemia, coagulation parameters were taken into account. The staged treatment involved stopping the bleeding, regulating the menstrual cycle and further preventing the bleeding. It has been found that uterine bleeding in reproductive age in the absence of etiopathogenetic treatment leads to the development of posthemorrhagic anemia. The severity and nature of bleeding is determined by the presence of defects in the platelet system of the hemostasis system with impaired platelet aggregation function. The study of total coagulation potential, primary hemostasis and the state of intravascular hemocoagulation in the patients using the methods for estimating the amount of platelet aggregation allows to detect and differentiate disorders in the hemostasis system. According to the results of the study, it can be concluded that the use of fibrinolysis inhibitors in the patients with abnormal uterine bleeding helps to increase the activity of the blood coagulation system and complete cessation of bleeding on the 2nd−5th day. Prophylactic administration of antifibrinolytic drugs from the first day of the menstrual cycle reduces blood loss, stabilizes menstrual function and significantly improves the psycho−emotional state of patients.

Key words: abnormal uterine bleeding, blood clotting, fibrinolysis inhibitors.

REFERENCES

1. Manukhin I. B., Tumilovich L. G., Gevorkyan M. A. Klinicheskie lektsii po endokrinnoi ginekologii. M.: Med. inform. agentstvo, 2001. 247 s.

2. Khadartseva K. A. Printsipy diagnostiki i lecheniya anomal'nykh matochnykh krovotechenii: metod. rek. po distsipline "Akusherstvo i ginekologiya". Tula, 2014. S. 6−12.

3. Chernukha G. E., Il'ina L. M., Ivanov I. A. Anomal'nye matochnye krovotecheniya: stavim diagnoz i vybiraem lechenie // Ginekologiya. 2018. T. 20, № 4. S. 4−8.

4. Vdovichenko Yu. P., Gopchuk E. N., Gerasimova T. V. Anomal'nye matochnye krovotecheniya reproduktivnogo vozrasta − sovremennoe sostoyanie problemy, sredstva korrektsii // Zdorov'e zhenshchiny. 2012. № 9 (75). S. 032−036.

5. Anomal'nye matochnye krovotecheniya pubertatnogo perioda: diagnostika i taktika lecheniya (obzor literatury) / L. V. Adamyan i dr. // Problemy reproduktsii. 2016. № 6. S. 51−55.

6. FIGO classification system (PALM−COEIN) for causes of abnormal uterine bleeding in nongravid women of 138 reproductive age. FIGO Working Group on Menstrual Disorders / M. G. Munro, H. O. Critchley, M. S. Broder, I. S. Fraser // Int. J. Gynaecol. Obstet. 2011. № 113. R. 3−13. doi: https://doi.org/10.1016/j.ijgo.2010.11.011

7. Osobennosti sostoyaniya endometriya u bol'nykh s anomal'nymi matochnymi krovotecheniyami / V. N. Gulieva i dr. // Akusherstvo, ginekologiya i reproduktsiya. 2014. T. 1, № 1. S. 12−14.

8. Lethaby A., Irvine G. A., Cameron I. T. Cyclical progestogens for heavy menstrual bleeding // Cochrane Database of Systematic Reviews. 2008. № 23 (1). CD 001016. doi: 10.1002/14651858 cd 001016 pub 2. review

9. Progestin−regulated expression of tissue factor in decidual cells: implications in endometrial hemostasis, menstruation and angiogenesis I II / F. Schatz et al. // Steroids. 2003. Vol. 68 (10−13). P. 849−860. doi: https://doi.org/10.1016/s0039−128x(03)00139−9

10. Kazak A. V. Klinicheskaya otsenka psikhologicheskikh osobennostei zhenshchin reproduktivnogo vozrasta s khronicheskimi anomal'nymi matochnymi krovotecheniyami // Reproduktivnoe zdorov'e. Vostochnaya Evropa. 2015. № 3 (39). S. 52−56.

11. Markin L. B., Chechuga S. B. Anomal'nye matochnye krovotecheniya − izmenilas' ne tol'ko terminologiya, no i kontseptual'nyi podkhod k probleme // Reproduktivnoe zdorov'e. Vostochnaya Evropa. 2015. № 3 (3−9). S. 104−117.

12. Timerbaev V. Kh., Valetova V. V. Rol' antifibrinolitikov (Traneksam) v sovremennoi ekstrennoi meditsine // Skoraya meditsinskaya pomoshch'. 2013. № 2. S. 51−61.

13. Dynnik V. A. Kharakteristika sistemy gemostaza u bol'nykh s anomal'nymi matochnymi krovotecheniyami pubertatnogo perioda // Perinatologiya i pediatriya. 2014. № 3 (59). S. 66.

14. Stepula V. V., Luk'yanchuk O. V., Rybin A. I. Profilaktika narushenii ovarial'no−menstrual'nogo tsikla u patsientok reproduktivnogo vozrasta posle fraktsionnogo vyskablivaniya matki // Reproduktivnoe zdorov'e zhenshchiny. 2008. № 2 (36). S. 120−122.

15. Tatarchuk T. F. Printsipy primeneniya progestagenov v ginekologii // Doktor. 2001. № 3. S. 39−42.

16. Queisser−Luft A. Dydrogesterone use during pregnancy: overview of birth defects reported since 1977 // Early Hum. Dev. 2009. P. 375−377. doi: https://doi.org/10.1016/j.earlhumdev.2008.12.016